Innovation & intellectual property · 04/10/2021Updated: 10/17/2026 · 1 min read
U.S. Patent Office Grants Interim Extension to GRAFAPEXT Patent
Summary
The United States Patent and Trademark Office has issued an order granting a one-year extension to the term of U.S. Patent No. 7,199,162, which covers the cancer treatment drug GRAFAPEXTM (dihydroxybusulfan).
Original source language: Federal Register — Patent and Trademark OfficeOpen original release →